Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,507 result(s) found for: Blood Disease. Displaying page 212 of 526.
    «« First « Previous 208  209  210  211  212  213  214  215  216  Next» Last»»
    EudraCT Number: 2005-005499-34 Sponsor Protocol Number: 11352A Start Date*: 2007-03-13
    Sponsor Name:H. Lundbeck A/S
    Full Title: A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000052-17 Sponsor Protocol Number: PK201301 Start Date*: 2013-10-07
    Sponsor Name:The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation
    Medical condition: Ewing sarcoma patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004882-26 Sponsor Protocol Number: ND-L02-s0201-002 Start Date*: 2015-03-25
    Sponsor Name:Nitto Denko Corporation
    Full Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-couple...
    Medical condition: Moderate to extensive progressive hepatic fibrosis (METAVIR F3-4)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001747-69 Sponsor Protocol Number: GEMII-1 Start Date*: 2011-10-28
    Sponsor Name:Monash University [...]
    1. Monash University
    2. NHS Lothian
    Full Title: Combination gefitinib and methotrexate to treat ectopic pregnancies II
    Medical condition: Ectopic pregnancy or pregnancy of unknown location.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10036585 - Pregnancy, puerperium and perinatal conditions 10014166 Ectopic pregnancy PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001023-21 Sponsor Protocol Number: DRL-17822/CD/004 Start Date*: 2011-06-30
    Sponsor Name:DR. REDDY'S LABORATORIES LIMITED
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia
    Medical condition: Hyperlipidemia Type II
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10045254 Type II hyperlipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002509-78 Sponsor Protocol Number: BOPPP Start Date*: 2019-04-24
    Sponsor Name:Kings College Hospital NHS Foundation Trust
    Full Title: Beta-blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP Trial). A blinded, UK multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.
    Medical condition: Liver cirrhosis with small oesophageal varices
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    21.1 100000004856 10055489 Esophageal varices in cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002531-18 Sponsor Protocol Number: 69HCL16_0062 Start Date*: 2018-10-31
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex. A phase II/III, multicentre, randomized, double-blind, placebo-controlled st...
    Medical condition: angiofibromas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002429 Angiofibroma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003510-25 Sponsor Protocol Number: 2014-PT029 Start Date*: 2016-01-25
    Sponsor Name:XBiotech USA, Inc.
    Full Title: A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized with Bacteremia Due to Staphylococcus Aureus
    Medical condition: Staphylococcus aereus Bacteremia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001684-89 Sponsor Protocol Number: RG_20-030 Start Date*: 2020-05-05
    Sponsor Name:University of Birmingham
    Full Title: CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003286-14 Sponsor Protocol Number: D3560L00060 Start Date*: 2006-09-18
    Sponsor Name:AstraZeneca UK Ltd
    Full Title: A phase IV, 6-week, randomised, double-blind, multicentre, parallel group, comparative study to evaluate the efficacy of rosuvastatin 5 mg and atorvastatin 10 mg in UK Asian subjects with primary h...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011279-56 Sponsor Protocol Number: IBU/20mg/2009 Start Date*: 2009-07-31
    Sponsor Name:Orphan Europe Recordati
    Full Title: Multicenter open-label pilot study to evaluate the safety, pharmacology and efficacy of a new dose regimen (i.e. 20-10-10 mg/kg) of Pedea (intravenous ibuprofen) in preterm newborn infants of less ...
    Medical condition: Hemodynamically significant persisting ductus arteriosus in preterm infants of less than 28 weeks of gestational age
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034130 Patent ductus arteriosus LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023217-61 Sponsor Protocol Number: 10/0174 Start Date*: 2012-01-27
    Sponsor Name:University College London
    Full Title: A phase IV, open-label, partial cross-over partial parallel, randomized, multi-centre study to compare the gastrointestinal tolerability of once daily oral deferasirox, when administered before or ...
    Medical condition: transfusional haemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10019024 Haemosiderosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000493-19 Sponsor Protocol Number: DZBL-2014-2 Start Date*: 2014-07-11
    Sponsor Name:Diabeteszentrum Bad Lauterberg
    Full Title: A randomized, controlled, prospective trial examining the effectiveness of two insulin titration algorithms of long acting insulin (insulin glargine, Lantus® or insulin detemir, Levemir®) in subjec...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004866-33 Sponsor Protocol Number: CA-BP13 Start Date*: 2014-04-04
    Sponsor Name:Göteborgs Universitet
    Full Title: A short term open, randomized cross over trial trial exploring the effect of carbonic anhydrase inhibition by acetazolamide on sleep apnea associated hypertension
    Medical condition: obstructive sleep apnea related hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019665-28 Sponsor Protocol Number: 10-HM11260C-201 Start Date*: 2010-05-07
    Sponsor Name:Hanmi Pharmaceutical Company Limited
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000753-31 Sponsor Protocol Number: HZA102942 Start Date*: 2012-03-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to invstigate the safety, tolerability,pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoa...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002198-37 Sponsor Protocol Number: ENHVIE Start Date*: 2016-09-19
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE - IDIBELL
    Full Title: A single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tac...
    Medical condition: Left ventricular hypertrophy in renal transplant patients in the maintenance phase .
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002060-40 Sponsor Protocol Number: C38072-AS-10069 Start Date*: 2017-07-11
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001501-14 Sponsor Protocol Number: 2013/142/HP Start Date*: 2016-02-26
    Sponsor Name:Rouen University Hospital
    Full Title: Pilot study of aprepitant effect on aldosterone secretion in diabetic patient (diabetes mellitus) with hypertension associated with low renin
    Medical condition: Diabetic patient (diabetes mellitus) with hypertension associated with low renin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10052741 Endocrine and metabolic secondary hypertension HLT
    18.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 208  209  210  211  212  213  214  215  216  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 03:09:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA